Recommended Adult Immunization ScheduleUnited States - 2016

Note: These recommendations must be read with the footnotes that follow
containing number of doses, intervals between doses, and other important information.

Figure 1. Recommended immunization schedule for adults aged 19 years or older, by vaccine and age group1
VACCINE AGE GROUP 19-21 years 22-26 years 27-49 years 50-59 years 60-64 years 65 years

Influenza *,2
1 dose annually

Tetanus, diphtheria, pertussis (Td/Tdap) *,3

Substitute Tdap for Td once, then Td booster every 10 yrs

Varicella*,4 2 doses

Human papillomavirus (HPV) Female*,5 3 doses

Human papillomavirus (HPV) Male*,5 3 doses

Zoster 6
1 dose

Measles, mumps, rubella (MMR) *,7

1 or 2 doses depending on indication
*,8
Pneumococcal 13-valent conjugate (PCV13) 1 dose

Pneumococcal 23-valent polysaccharide (PPSV23) 8

1 or 2 doses depending on indication 1 dose

Hepatitis A *,9
2 or 3 doses depending on vaccine

Hepatitis B *,10 3 doses

Meningococcal 4-valent conjugate (MenACWY) or 1 or more doses depending on indication
polysaccharide (MPSV4)*,11
Meningococcal B (MenB)11 2 or 3 doses depending on vaccine

Haemophilus influenzae type b (Hib)*,12 1 or 3 doses depending on indication

*Covered by the Vaccine Injury Compensation Program Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS
report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.
Recommended for all persons who
meet the age requirement, lack Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a
documentation of vaccination, or claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
lack evidence of past infection; zoster
vaccine is recommended regardless of Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at
past episode of zoster www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 8:00 a.m. - 8:00 p.m. Eastern Time, Monday -
Friday, excluding holidays.
Recommended for persons with a risk
factor (medical, occupational, lifestyle, Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
or other indication)
The recommendations in this schedule were approved by the Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization Practices
No recommendation (ACIP), the American Academy of Family Physicians (AAFP), the America College of Physicians (ACP), the American College of Obstetricians and Gynecologists (ACOG)
and the American College of Nurse-Midwives (ACNM).

Figure 2. Vaccines that might be indicated for adults aged 19 years or older based on medical and other indications1
Immuno- HIV infection Men who Kidney failure, Heart disease,
compromising CD4+ count have sex end-stage renal chronic lung Asplenia and persistent Chronic
conditions (excluding (cells/L) 4,6,7,8,13 with men disease, on disease, chronic complement component liver Healthcare
VACCINE INDICATION Pregnancy HIV infection) 4,6,7,8,13 < 200 200 (MSM) hemodialysis alcoholism deficiencies 8,11,12 disease Diabetes personnel

Influenza*,2 1 dose annually

1 dose Tdap each
Tetanus, diphtheria, pertussis (Td/Tdap)*,3 pregnancy Substitute Tdap for Td once, then Td booster every 10 yrs

Varicella*,4 Contraindicated 2 doses

Human papillomavirus (HPV) Female*,5 3 doses through age 26 yrs 3 doses through age 26 yrs

Human papillomavirus (HPV) Male*,5 3 doses through age 26 yrs 3 doses through age 21 yrs

Zoster6 Contraindicated 1 dose

Measles, mumps, rubella (MMR)*,7 Contraindicated 1 or 2 doses depending on indication

Pneumococcal 13-valent conjugate (PCV13)*,8 1 dose

Pneumococcal polysaccharide (PPSV23)8 1, 2, or 3 doses depending on indication

Hepatitis A*,9 2 or 3 doses depending on vaccine

Hepatitis B*,10 3 doses

Meningococcal 4-valent conjugate (MenACWY) 1 or more doses depending on indication

or polysaccharide (MPSV4)*,11
Meningococcal B (MenB)11 2 or 3 doses depending on vaccine

Haemophilus influenzae type b (Hib)*,12 3 doses post-HSCT 1 dose

recipients only
*Covered by the Recommended for all persons who meet the age requirement, lack Recommended for persons with a risk No recommendation Contraindicated
Vaccine Injury documentation of vaccination, or lack evidence of past infection; factor (medical, occupational, lifestyle, or
Compensation zoster vaccine is recommended regardless of past episode of zoster other indication)
Program
These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly
recommended for adults aged 19 years, as of February 2016. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does
not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the
combination are indicated and when the vaccines other components are not contraindicated. For detailed recommendations on all vaccines, including those used
primarily for travelers or that are issued during the year, consult the manufacturers package inserts and the complete statements from the Advisory Committee on
Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identification only and does not
imply endorsement by the U.S. Department of Health and Human Services.
FootnotesRecommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016
1. Additional information HPV vaccines are not recommended for use in pregnant women. However,
Additional guidance for the use of the vaccines described in this supplement is pregnancy testing is not needed before vaccination. If a woman is found to be
available at www.cdc.gov/vaccines/hcp/acip-recs/index.html. pregnant after initiating the vaccination series, no intervention is needed; the
Information on vaccination recommendations when vaccination status is remainder of the 3-dose series should be delayed until completion or termination
unknown and other general immunization information can be found in the of pregnancy.
General Recommendations on Immunization at 6. Zoster vaccination
www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm. A single dose of zoster vaccine is recommended for adults aged 60 years
Information on travel vaccine requirements and recommendations (e.g., for regardless of whether they report a prior episode of herpes zoster. Although
hepatitis A and B, meningococcal, and other vaccines) is available at the vaccine is licensed by the U.S. Food and Drug Administration for use among
wwwnc.cdc.gov/travel/destinations/list. and can be administered to persons aged 50 years, ACIP recommends that
Additional information and resources regarding vaccination of pregnant women vaccination begin at age 60 years.
can be found at www.cdc.gov/vaccines/adults/rec-vac/pregnant.html. Persons aged 60 years with chronic medical conditions may be vaccinated
2. Influenza vaccination unless their condition constitutes a contraindication, such as pregnancy or severe
Annual vaccination against influenza is recommended for all persons aged 6 immunodeficiency.
months. A list of currently available influenza vaccines can be found at http:// 7. Measles, mumps, rubella (MMR) vaccination
www.cdc.gov/flu/protect/vaccine/vaccines.htm. Adults born before 1957 are generally considered immune to measles and mumps.
Persons aged 6 months, including pregnant women, can receive the inactivated All adults born in 1957 or later should have documentation of 1 or more doses
influenza vaccine (IIV). An age-appropriate IIV formulation should be used. of MMR vaccine unless they have a medical contraindication to the vaccine or
Intradermal IIV is an option for persons aged 18 through 64 years. laboratory evidence of immunity to each of the three diseases. Documentation of
High-dose IIV is an option for persons aged 65 years. provider-diagnosed disease is not considered acceptable evidence of immunity for
Live attenuated influenza vaccine (LAIV [FluMist]) is an option for healthy, non- measles, mumps, or rubella.
pregnant persons aged 2 through 49 years. Measles component:
Recombinant influenza vaccine (RIV [Flublok]) is approved for persons aged 18 A routine second dose of MMR vaccine, administered a minimum of 28 days after
years. the first dose, is recommended for adults who:
RIV, which does not contain any egg protein, may be administered to persons are students in postsecondary educational institutions,
aged 18 years with egg allergy of any severity; IIV may be used with additional work in a health care facility, or
safety measures for persons with hives-only allergy to eggs. plan to travel internationally.
Health care personnel who care for severely immunocompromised persons Persons who received inactivated (killed) measles vaccine or measles vaccine of
who require care in a protected environment should receive IIV or RIV; health unknown type during 19631967 should be revaccinated with 2 doses of MMR
care personnel who receive LAIV should avoid providing care for severely vaccine.
immunosuppressed persons for 7 days after vaccination. Mumps component:
3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination A routine second dose of MMR vaccine, administered a minimum of 28 days after
Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy the first dose, is recommended for adults who:
(preferably during 2736 weeks gestation) regardless of interval since prior Td or are students in a postsecondary educational institution,
Tdap vaccination. work in a health care facility, or
Persons aged 11 years who have not received Tdap vaccine or for whom plan to travel internationally.
vaccine status is unknown should receive a dose of Tdap followed by tetanus Persons vaccinated before 1979 with either killed mumps vaccine or mumps
and diphtheria toxoids (Td) booster doses every 10 years thereafter. Tdap can be vaccine of unknown type who are at high risk for mumps infection (e.g., persons
administered regardless of interval since the most recent tetanus or diphtheria- who are working in a health care facility) should be considered for revaccination
toxoid-containing vaccine. with 2 doses of MMR vaccine.
Adults with an unknown or incomplete history of completing a 3-dose primary Rubella component:
vaccination series with Td-containing vaccines should begin or complete a primary For women of childbearing age, regardless of birth year, rubella immunity should
vaccination series including a Tdap dose. be determined. If there is no evidence of immunity, women who are not pregnant
For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the should be vaccinated. Pregnant women who do not have evidence of immunity
third dose 612 months after the second. should receive MMR vaccine upon completion or termination of pregnancy and
For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining before discharge from the health care facility.
doses. Health care personnel born before 1957:
Refer to the ACIP statement for recommendations for administering Td/Tdap as For unvaccinated health care personnel born before 1957 who lack laboratory
prophylaxis in wound management (see footnote 1). evidence of measles, mumps, and/or rubella immunity or laboratory confirmation
4. Varicella vaccination of disease, health care facilities should consider vaccinating personnel with 2
All adults without evidence of immunity to varicella (as defined below) should doses of MMR vaccine at the appropriate interval for measles and mumps or 1
receive 2 doses of single-antigen varicella vaccine or a second dose if they have dose of MMR vaccine for rubella.
received only 1 dose. 8. Pneumococcal vaccination
Vaccination should be emphasized for those who have close contact with persons General information
at high risk for severe disease (e.g., health care personnel and family contacts of Adults are recommended to receive 1 dose of 13-valent pneumococcal
persons with immunocompromising conditions) or are at high risk for exposure or conjugate vaccine (PCV13) and 1, 2, or 3 doses (depending on indication) of
transmission (e.g., teachers; child care employees; residents and staff members of 23-valent pneumococcal polysaccharide vaccine (PPSV23).
institutional settings, including correctional institutions; college students; military PCV13 should be administered at least 1 year after PPSV23.
personnel; adolescents and adults living in households with children; nonpregnant PPSV23 should be administered at least 1 year after PCV13, except among
women of childbearing age; and international travelers). adults with immunocompromising conditions, anatomical or functional
Pregnant women should be assessed for evidence of varicella immunity. Women asplenia, cerebrospinal fluid leak, or cochlear implant, for whom the interval
who do not have evidence of immunity should receive the first dose of varicella should be at least 8 weeks; the interval between PPSV23 doses should be at
vaccine upon completion or termination of pregnancy and before discharge from least 5 years.
the health care facility. The second dose should be administered 48 weeks after No additional dose of PPSV23 is indicated for adults vaccinated with PPSV23
the first dose. at age 65 years.
Evidence of immunity to varicella in adults includes any of the following: When both PCV13 and PPSV23 are indicated, PCV13 should be administered
documentation of 2 doses of varicella vaccine at least 4 weeks apart; first; PCV13 and PPSV23 should not be administered during the same visit.
U.S.-born before 1980, except health care personnel and pregnant women; When indicated, PCV13 and PPSV23 should be administered to adults whose
history of varicella based on diagnosis or verification of varicella disease by a pneumococcal vaccination history is incomplete or unknown.
health care provider; Adults aged 65 years (immunocompetent) who:
history of herpes zoster based on diagnosis or verification of herpes zoster have not received PCV13 or PPSV23: administer PCV13 followed by PPSV23 at
disease by a health care provider; or least 1 year after PCV13.
laboratory evidence of immunity or laboratory confirmation of disease. have not received PCV13 but have received a dose of PPSV23 at age 65 years:
5. Human papillomavirus (HPV) vaccination administer PCV13 at least 1 year after PPSV23.
Three HPV vaccines are licensed for use in females (bivalent HPV vaccine [2vHPV], have not received PCV13 but have received 1 or more doses of PPSV23 at
quadrivalent HPV vaccine [4vHPV], and 9-valent HPV vaccine [9vHPV]) and two age <65 years: administer PCV13 at least 1 year after the most recent dose of
HPV vaccines are licensed for use in males (4vHPV and 9vHPV). PPSV23. Administer a dose of PPSV23 at least 1 year after PCV13 and at least 5
For females, 2vHPV, 4vHPV, or 9vHPV is recommended in a 3-dose series for years after the most recent dose of PPSV23.
routine vaccination at age 11 or 12 years and for those aged 13 through 26 years, if have received PCV13 but not PPSV23 at age <65 years: administer PPSV23 at
not previously vaccinated. least 1 year after PCV13.
For males, 4vHPV or 9vHPV is recommended in a 3-dose series for routine have received PCV13 and 1 or more doses of PPSV23 at age <65 years:
vaccination at age 11 or 12 years and for those aged 13 through 21 years, if not administer PPSV23 at least 1 year after PCV13 and at least 5 years after the
previously vaccinated. Males aged 22 through 26 years may be vaccinated. most recent dose of PPSV23.
HPV vaccination is recommended for men who have sex with men through age 26 Adults aged 19 years with immunocompromising conditions or anatomical or
years who did not get any or all doses when they were younger. functional asplenia (defined below) who:
Vaccination is recommended for immunocompromised persons (including those have not received PCV13 or PPSV23: administer PCV13 followed by PPSV23 at
with HIV infection) through age 26 years who did not get any or all doses when least 8 weeks after PCV13. Administer a second dose of PPSV23 at least 5 years
they were younger. after the first dose of PPSV23.
A complete HPV vaccination series consists of 3 doses. The second dose should have not received PCV13 but have received 1 dose of PPSV23: administer
be administered 48 weeks (minimum interval of 4 weeks) after the first dose; the PCV13 at least 1 year after the PPSV23. Administer a second dose of PPSV23 at
third dose should be administered 24 weeks after the first dose and 16 weeks after least 8 weeks after PCV13 and at least 5 years after the first dose of PPSV23.
the second dose (minimum interval of 12 weeks).
(Continued on next page)
FootnotesRecommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016
have not received PCV13 but have received 2 doses of PPSV23: administer programs and facilities for chronic hemodialysis patients, and institutions and
PCV13 at least 1 year after the most recent dose of PPSV23. nonresidential day care facilities for persons with developmental disabilities.
have received PCV13 but not PPSV23: administer PPSV23 at least 8 weeks after Administer missing doses to complete a 3-dose series of hepatitis B vaccine to
PCV13. Administer a second dose of PPSV23 at least 5 years after the first dose those persons not vaccinated or not completely vaccinated. The second dose
of PPSV23. should be administered at least 1 month after the first dose; the third dose should
have received PCV13 and 1 dose of PPSV23: administer a second dose of be administered at least 2 months after the second dose (and at least 4 months
PPSV23 at least 8 weeks after PCV13 and at least 5 years after the first dose of after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix)
PPSV23. is used, give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule
If the most recent dose of PPSV23 was administered at age <65 years, at age may be used, administered on days 0, 7, and 2130, followed by a booster dose at
65 years, administer a dose of PPSV23 at least 8 weeks after PCV13 and at 12 months.
least 5 years after the last dose of PPSV23. Adult patients receiving hemodialysis or with other immunocompromising
Immunocompromising conditions that are indications for pneumococcal conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered
vaccination are: congenital or acquired immunodeficiency (including B- or on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B)
T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.
excluding chronic granulomatous disease), HIV infection, chronic renal failure, 11. Meningococcal vaccination
nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized General information
malignancy, multiple myeloma, solid organ transplant, and iatrogenic Serogroup A, C, W, and Y meningococcal vaccine is available as a conjugate
immunosuppression (including long-term systemic corticosteroids and (MenACWY [Menactra, Menveo]) or a polysaccharide (MPSV4 [Menomune])
radiation therapy). vaccine.
Anatomical or functional asplenia that are indications for pneumococcal Serogroup B meningococcal (MenB) vaccine is available as a 2-dose series of
vaccination are: sickle cell disease and other hemoglobinopathies, congenital MenB-4C vaccine (Bexsero) administered at least 1 month apart or a 3-dose
or acquired asplenia, splenic dysfunction, and splenectomy. Administer series of MenB-FHbp (Trumenba) vaccine administered at 0, 2, and 6 months;
pneumococcal vaccines at least 2 weeks before immunosuppressive therapy the two MenB vaccines are not interchangeable, i.e., the same MenB vaccine
or an elective splenectomy, and as soon as possible to adults who are newly product must be used for all doses.
diagnosed with asymptomatic or symptomatic HIV infection. MenACWY vaccine is preferred for adults with serogroup A, C, W, and Y
Adults aged 19 years with cerebrospinal fluid leaks or cochlear implants: meningococcal vaccine indications who are aged 55 years, and for adults
administer PCV13 followed by PPSV23 at least 8 weeks after PCV13; no additional aged 56 years: 1) who were vaccinated previously with MenACWY vaccine
dose of PPSV23 is indicated if aged <65 years. If PPSV23 was administered at age and are recommended for revaccination or 2) for whom multiple doses of
<65 years, at age 65 years, administer another dose of PPSV23 at least 5 years vaccine are anticipated; MPSV4 vaccine is preferred for adults aged 56 years
after the last dose of PPSV23. who have not received MenACWY vaccine previously and who require a single
Adults aged 19 through 64 years with chronic heart disease (including congestive dose only (e.g., persons at risk because of an outbreak).
heart failure and cardiomyopathies, excluding hypertension), chronic lung disease Revaccination with MenACWY vaccine every 5 years is recommended for
(including chronic obstructive lung disease, emphysema, and asthma), chronic adults previously vaccinated with MenACWY or MPSV4 vaccine who remain at
liver disease (including cirrhosis), alcoholism, or diabetes mellitus, or who smoke increased risk for infection (e.g., adults with anatomical or functional asplenia
cigarettes: administer PPSV23. At age 65 years, administer PCV13 at least 1 year or persistent complement component deficiencies, or microbiologists who
after PPSV23, followed by another dose of PPSV23 at least 1 year after PCV13 and are routinely exposed to isolates of Neisseria meningitidis).
at least 5 years after the last dose of PPSV23. MenB vaccine is approved for use in persons aged 10 through 25 years;
Routine pneumococcal vaccination is not recommended for American Indian/ however, because there is no theoretical difference in safety for persons aged
Alaska Native or other adults unless they have an indication as above; however, >25 years compared to those aged 10 through 25 years, MenB vaccine is
public health authorities may consider recommending the use of pneumococcal recommended for routine use in persons aged >10 years who are at increased
vaccines for American Indians/Alaska Natives or other adults who live in areas with risk for serogroup B meningococcal disease.
increased risk for invasive pneumococcal disease. There is no recommendation for MenB revaccination at this time.
9. Hepatitis A vaccination MenB vaccine may be administered concomitantly with MenACWY vaccine
Vaccinate any person seeking protection from hepatitis A virus (HAV) infection and but at a different anatomic site, if feasible.
persons with any of the following indications: HIV infection is not an indication for routine vaccination with MenACWY
men who have sex with men; or MenB vaccine; if an HIV-infected person of any age is to be vaccinated,
persons who use injection or noninjection illicit drugs; administer 2 doses of MenACWY vaccine at least 2 months apart.
persons working with HAV-infected primates or with HAV in a research Adults with anatomical or functional asplenia or persistent complement
laboratory setting; component deficiencies: administer 2 doses of MenACWY vaccine at least 2
persons with chronic liver disease and persons who receive clotting factor months apart and revaccinate every 5 years. Also administer a series of MenB
concentrates; vaccine.
persons traveling to or working in countries that have high or intermediate Microbiologists who are routinely exposed to isolates of Neisseria meningitidis:
endemicity of hepatitis A (see footnote 1); and administer a single dose of MenACWY vaccine; revaccinate with MenACWY
unvaccinated persons who anticipate close personal contact (e.g., household vaccine every 5 years if remain at increased risk for infection. Also administer a
or regular babysitting) with an international adoptee during the first 60 days series of MenB vaccine.
after arrival in the United States from a country with high or intermediate Persons at risk because of a meningococcal disease outbreak: if the outbreak
endemicity of hepatitis A (see footnote 1). The first dose of the 2-dose is attributable to serogroup A, C, W, or Y, administer a single dose of MenACWY
hepatitis A vaccine series should be administered as soon as adoption is vaccine; if the outbreak is attributable to serogroup B, administer a series of MenB
planned, ideally 2 or more weeks before the arrival of the adoptee. vaccine.
Single-antigen vaccine formulations should be administered in a 2-dose schedule Persons who travel to or live in countries in which meningococcal disease is
at either 0 and 612 months (Havrix), or 0 and 618 months (Vaqta). If the hyperendemic or epidemic: administer a single dose of MenACWY vaccine
combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses and revaccinate with MenACWY vaccine every 5 years if the increased risk for
at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered infection remains (see footnote 1); MenB vaccine is not recommended because
on days 0, 7, and 2130 followed by a booster dose at 12 months. meningococcal disease in these countries is generally not caused by serogroup B.
10. Hepatitis B vaccination Military recruits: administer a single dose of MenACWY vaccine.
Vaccinate any person seeking protection from hepatitis B virus (HBV) infection and First-year college students aged 21 years who live in residence halls: administer a
persons with any of the following indications: single dose of MenACWY vaccine if they have not received a dose on or after their
sexually active persons who are not in a long-term, mutually monogamous 16th birthday.
relationship (e.g., persons with more than 1 sex partner during the previous 6 Young adults aged 16 through 23 years (preferred age range is 16 through 18
months); persons seeking evaluation or treatment for a sexually transmitted years): may be vaccinated with a series of MenB vaccine to provide short-term
disease (STD); current or recent injection drug users; and men who have sex protection against most strains of serogroup B meningococcal disease.
with men; 12. Haemophilus influenzae type b (Hib) vaccination
health care personnel and public safety workers who are potentially exposed One dose of Hib vaccine should be administered to persons who have anatomical
to blood or other infectious body fluids; or functional asplenia or sickle cell disease or are undergoing elective splenectomy
persons who are aged <60 years with diabetes as soon as feasible after if they have not previously received Hib vaccine. Hib vaccination 14 or more days
diagnosis; persons with diabetes who are aged 60 years at the discretion before splenectomy is suggested.
of the treating clinician based on the likelihood of acquiring HBV infection, Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated
including the risk posed by an increased need for assisted blood glucose with a 3-dose regimen 612 months after a successful transplant, regardless of
monitoring in long-term care facilities, the likelihood of experiencing chronic vaccination history; at least 4 weeks should separate doses.
sequelae if infected with HBV, and the likelihood of immune response to Hib vaccine is not recommended for adults with HIV infection since their risk for
vaccination; Hib infection is low.
persons with end-stage renal disease (including patients receiving 13. Immunocompromising conditions
hemodialysis), persons with HIV infection, and persons with chronic liver Inactivated vaccines (e.g., pneumococcal, meningococcal, and inactivated
disease; influenza vaccines) generally are acceptable and live vaccines generally should
household contacts and sex partners of hepatitis B surface antigen be avoided in persons with immune deficiencies or immunocompromising
positive persons, clients and staff members of institutions for persons with conditions. Information on specific conditions is available at www.cdc.gov/
developmental disabilities, and international travelers to regions with high or vaccines/hcp/acip-recs/index.html.
intermediate levels of endemic HBV infection (see footnote 1); and
all adults in the following settings: STD treatment facilities, HIV testing and
treatment facilities, facilities providing drug abuse treatment and prevention
services, health care settings targeting services to injection drug users or
men who have sex with men, correctional facilities, end-stage renal disease